

AD _____

Award Number: DAMD17-00-1-0080

TITLE: The Emory University Prostate Cancer Center Initiation Award

PRINCIPAL INVESTIGATOR: John A. Petros, M.D.

CONTRACTING ORGANIZATION: Emory University School of Medicine
Atlanta GA 30322

REPORT DATE: April 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-04-2004		2. REPORT TYPE Final		3. DATES COVERED (From - To) 01 Apr 00 – 31 Mar 04	
4. TITLE AND SUBTITLE The Emory University Prostate Cancer Center Initiation Award				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-00-1-0080	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) John A. Petros, M.D. E-Mail: ipetros@emory.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Emory University School of Medicine Atlanta GA 30322				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: None provided.					
15. SUBJECT TERMS None provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	11	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....	4
Body.....	5
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusions.....	8
References.....	9
Appendices.....	

Introduction

This award has funded the development of a multidisciplinary prostate cancer research consortium at Emory University. During the funding period a consortium has been developed and matured. The specific research projects funded have all been successful with resultant publications and NIH grants as tangible evidence of progress and success. In addition, the dynamic prostate cancer research supported by this award has aided in the recruitment of one of the largest and most well recognized prostate cancer research groups to Emory (Dr. Leland Chung and his associates). In part because of the research environment created by this award, another key recruit has just been completed in the Department of Pathology (Dr. Milton Datta) further enhancing our capabilities in translational prostate cancer research. Since the funding of this award, Dr. Petros has been awarded an RO1 and a project in a PO1 based directly upon work funded by this Department of Defense center award. Dr. Lambeth has been awarded an RO1 similarly based upon DOD funded work. Fundamental new knowledge has been generated in the areas of mitochondrial DNA mutations in prostate cancer, reactive oxygen signaling in prostate cancer and the importance of MUC-18 in prostate cancer metastases. There are multiple publications from each of the three projects funded documenting this new knowledge. In summary, the goals of this award have been accomplished with grants and publications as tangible documentation of this success.

Body and Key Research Accomplishments

The project, now completed (including one year no-cost extension) has had essentially all of the findings published. These manuscripts constitute the bulk of the reportable outcomes and constitute the scientific report required for this final report.

The project included a pathology and technology development core, the accomplishments of which are reported in #1 below. Project #3 involved MUC-18 in prostate cancer and is summarized in #2 below. Project #1 involved reactive oxygen and NOX (previously Mox) enzyme expression and is summarized in #3 below. Project #2 involved reactive oxygen and novel tumor signatures which are reported in #4-6 below. This includes the discovery of a new candidate oncogene and a new candidate tumor suppressor gene.

1. Development of technical capabilities to support translational prostate cancer work.

a. Dr. Amin developed a method for procuring specific populations of viable human prostate cancer cells for research (Reference 2, attached as appendix).

b. Dr. Amin developed methodology for analysis of immunohistochemical analysis of prostate biopsies (References 8 and 9, attached as appendix).

c. Dr. Petros developed methodology for automated sequencing of complete mitochondrial genomes from laser capture microdissected (LCM) prostate samples (Reference 12, attached as appendix).

d. Dr. Petros developed methods for high efficiency transfection of prostate cancer cells using electroporation (Reference 1, attached as appendix).

2. Analysis of the importance of the cell adhesion molecule MUC-18.

a. Drs. Wu, Petros and Amin described the expression patterns of MUC-18 in clinical prostate cancer specimens (Reference 4, attached as appendix).

b. Drs. Wu, Petros and Amin cloned the MUC-18 gene and correlated expression levels with malignant progression (Reference 5, attached as appendix).

c. Dr. Wu demonstrated that ectopic expression of MUC-18 increased metastatic potential of prostate cancer cells (Reference 15, attached as appendix).

3. Analysis of the importance of NOX enzymes in prostate cancer.

a. Drs. Arnold, Lambeth and Petros demonstrated that hydrogen peroxide mediates the transforming properties of Nox in prostate cancer (Reference 3, attached as appendix).

b. Drs. Arnold, Lambeth and Petros demonstrated that Nox1 triggers the angiogenic switch in prostate cancer (Reference 7, attached as appendix).

c. Dr. Arnold demonstrated that NOX5 regulates growth and apoptosis of prostate cancer (Reference 12, attached as appendix).

4. Drs. Petros, Marshall and Wallace demonstrated the age-associated accumulation of mitochondrial DNA (mtDNA) mutations in prostate cancer (Reference 6, attached as appendix).

5. Drs. Petros, Young and Marshall showed that the expression of beta defensin 1 (initially found on tumor gene expression array analysis) is decreased in prostate and renal cancer, suggesting that this may be one of the chromosome 8p tumor suppressor genes.

6. Drs. Petros and Marshall identified a novel gene (PrLZ) that may be one of the oncogenes on chromosome 8q, accounting for the frequent observation of amplification of this chromosome in clinical prostate cancer (Reference 14, attached as appendix).

Reportable Outcomes:

I. Published manuscripts (14 published manuscripts, listed in references and explained in “body and key research accomplishments”).

II. Grants

Note: Dr. Petros is PI or co-investigator on all of these grants. Those listed below as “A”, “B” and “D” had data generated by this DOD grant included in preliminary data and are thus directly consequent to the funding of this award. The center grant “C” below was enabled by the consortium developed in this DOD award, as was the program project grant (“A” below).

A. 1PO1 CA98912 (Chung)	08/01/03 – 07/31/08			
28% (Co-PI and Project Leader)	\$ (Annual, Direct)			
Prostate Cancer Bone Metastasis: Biology and Targeting				
B. 1RO1 CA96994-01 (Petros)	08/01/02 – 07/31-07			
30% (PI)				
NIH	\$1,	(Total)	\$	(Current)
Mitochondrial DNA Mutations in Prostate Cancer				
C. 1 P20 CA103735 (Simons)	07/01/03 – 06/30/08			
10% (Prostate Cancer Program Co-Director)				
NIH	\$	(Total)	\$	(Current)
Winship Cancer Institute, Emory University Planning Grant				
D. 1RO1 CA84138 (Lambeth)	01/05/00 – 12/31/04			
8% (Collaborator)				
NIH	\$	(Total)	\$	(current)
Mox1: A novel mitogenic oxidase				

III. Abstracts:

Petros, JA, Sun CQ, Irons H, Donald C, Amin MB, Lim SD, Hosseini S, Marshall FF, Wallace DC. Mitochondrial DNA mutations in prostate cancer. J Urol. 165 (5) Supl: 137, A563, 2001

Jessie BC, **Sun QC, Irons H, Marshall FF, Wallace DC, Petros JA.** Accumulation of mitochondrial DNA deletions in the aging prostate. J Urol. 165 (5) Supl: 138, A567, 2001

Petros JA, Sun QC, Irons H, Donald C, Amin M, Lim SD, Hosseini S, Marshall FF, Wallace DC. Mitochondrial DNA point mutations re common in prostate cancer and enhance malignant phenotype. Proceedings of the American Association for Cancer Research 42: 517, A2781, 2001.

Sun QC, Irons H, Arnold R, Lambeth JD, Marshall FF, Petros JA. Nox1 transfected prostate cancer cell line DU145 shown increased tumorigenesis and proliferation rates. Proceedings of the American Association for Cancer Research 42: 527, A2838, 2001.

Jessie BC, **Sun QC, Irons H, Marshall FF, Simons J, Wallace DC, Petros JA.** Accumulation of mitochondrial DNA deletions in the aging prostate. Proceedings of the American Association for Cancer Research 42: 862, A4624, 2001.

IV. Cell lines:

Cell Lines:

Wu (Project 3): Several cell lines derived from LNCaP that express MUC-18

Petros (Project 2): Cybrid cell lines with the 8993 mutation in PC3.

Arnold (Project 1): Nox-1 expressing lines derived from DU-145.

Conclusions:

1. This DOD center award was successful in both novel research discoveries and initiation of a vital multidisciplinary prostate cancer research group at Emory.
2. Multiple grants have been funded as a direct result of this award.
3. Multiple scientific manuscripts have resulted from this work.
4. The investment made by the US government in this award has been substantially leveraged to allow ongoing discovery well beyond the period of the award

REFERENCES

1. Canatella PJ, Karr JF, **Petros JA**, Prausnitz MR. **Quantitative study of electroporation-mediated molecular uptake and cell viability**. [Journal Article] *Biophysical Journal*. 80(2):755-64, 2001 Feb
2. Fischer AH, Philips A, Taysavang P, McKenney JK, **Amin MB**. **Method for procuring specific populations of viable human prostate cells for research**. [Evaluation Studies. Journal Article] *Laboratory Investigation*. 81(4):501-7, 2001 Apr.
3. Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, **Petros JA**, Lambeth JD. **Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1**. [Journal Article] *Proceedings of the National Academy of Sciences of the United States of America*. 98(10):5550-5, 2001 May 8.
4. Wu GJ, Varma VA, Wu MW, Wang SW, Qu P, Yang H, Petros JA, Lim SD, Amin MB. **Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues**. [Journal Article] *Prostate*. 48(4):305-15, 2001 Sep 15.
5. Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB. **Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression**. [Journal Article] *Gene*. 279(1):17-31, 2001 Nov 14.
6. Jessie BC, Sun CQ, Irons HR, Marshall FF, Wallace DC, **Petros JA**. **Accumulation of mitochondrial DNA deletions in the malignant prostate of patients of different ages**. [Journal Article] *Experimental Gerontology*. 37(1):169-74, 2001 Dec.
7. Arbiser JL, **Petros J**, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, Lambeth JD. **Reactive oxygen generated by Nox1 triggers the angiogenic switch**. [Journal Article] *Proceedings of the National Academy of Sciences of the United States of America*. 99(2):715-20, 2002 Jan 22.
8. Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PG, **Amin MB**. **Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice**. [Journal Article] *Archives of Pathology & Laboratory Medicine*. 126(5):554-61, 2002 May.
9. Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, Grignon DJ, Fanger GR, **Amin MB**. **P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies**. [Journal Article] *American Journal of Surgical Pathology*. 26(12):1588-96, 2002 Dec.
10. Donald CD, Sun CQ, Lim SD, Macoska J, Cohen C, Amin MB, **Young AN**, Ganz TA, Marshall FF, Petros JA. **Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas**. [Journal Article. Validation Studies] *Laboratory Investigation*. 83(4):501-5, 2003 Apr.
11. Brar SS, Corbin Z, Kennedy TP, Hemendinger R, Thornton L, Bommarius B, **Arnold RS**, Whorton AR, Sturrock AB, Huecksteadt TP, Quinn MT, Krenitsky K, Ardie KG, Lambeth JD, Hoidal JR. **NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells**. [Journal Article] *American Journal of Physiology - Cell Physiology*. 285(2):C353-69, 2003 Aug.
12. Aldridge BA, Lim SD, Baumann AK, Hosseini S, Buck W, Almekinder TL, Sun CQ, **Petros JA**. **Automated sequencing of complete mitochondrial genomes from laser-capture microdissected samples**. [Evaluation Studies. Journal Article] *Biotechniques*. 35(3):606-7, 609-10, 612, 2003 Sep.

13. Wang R. Xu J. Saramaki O. Visakorpi T. Sutherland WM. Zhou J. Sen B. Lim SD. Mabjeesh N. Amin M. Dong JT. **Petros** JA. Nelson PS. Marshall FF. Zhau HE. Chung LW. **PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer.** [Journal Article] *Cancer Research*. 64(5):1589-94, 2004 Mar 1.
14. Wu GJ. Peng Q. Fu P. Wang SW. Chiang CF. Dillehay DL. Wu MW. **Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells.** [Journal Article] *Gene*. 327(2):201-13, 2004 Mar 3.